Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn(University of California, Los Angeles), Dennis J. Slamon(University of California, Los Angeles), Oleg Lipatov(UCSF Helen Diller Family Comprehensive Cancer Center), Véronique Dièras(Institut Curie), Dongrui R. Lu(Pfizer (United States)), Karen A. Gelmon(University of British Columbia), Stephen E. Jones(Cleveland Clinic), Seock‐Ah Im(Seoul National University), Sophia Randolph(Pfizer (United States)), Janice M. Walshe(Cancer Trials Ireland), Hope S. Rugo(City of Hope), Miguel Martín(Hospital General Universitario Gregorio Marañón), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Eric Gauthier(Pfizer (United States)), Nadia Harbeck(Breast Center)
Cited by 2,939
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k